Abstract
IntroductionIn clinical studies, delayed-release dimethyl fumarate (DMF) demonstrated a favorable benefit-risk profile in patients with relapsing-remitting multiple sclerosis (MS). Real-world studies enable char- acterization of risks that may emerge with...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have